Loading...
Regencell Bioscience Holdings Limited
RGC•NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$695.00
$70.05(11.21%)
Regencell Bioscience Holdings Limited (RGC) Stock Overview
Explore Regencell Bioscience Holdings Limited’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.17
↑ 26.73%
EPS Growth
$-0.17
↑ 26.67%
Operating Margin
0.00%
↑ 24.50%
ROE
-25.23%
↑ 26.73%
Dividend Yield
0.00%
Analyst Recommendations data is not available for RGCAnalyst Recommendations details for RGC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
CEO
Mr. Yat-Gai Au
Employees
12
Headquarters
First Commercial Building, Causeway Bay
Founded
2021